statistically

[키워드] 1:1 105 patient 105 patients 95% CI activity acute respiratory syndrome administration Adverse adverse events age all-cause mortality anti-inflammatory action biochemical C-reactive protein cardiac cardiac troponin caution clinical clinical benefit Clinical deterioration clinical end point Clinical outcome clinical outcomes clinical status clinical trial Colchicine colchicine group Complication Concentration control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 death Deterioration diarrhea dimerized Effect effect of treatment efficacy analysis end point evaluate evaluate the effect evaluated event except for finding followed by global pandemic Greece groups hospital Hospitalized Identifier Importance increase in Infection Inflammatory biomarker intention-to-treat basis interquartile range Loading dose log rank maintenance dose measure mechanical ventilation median no difference no significant difference no significant differences normal activities objective Odds ratio Open-label participant Patient patients patients hospitalized plasma fragment D Point prevention primary end point Randomized randomized clinical trial receipt Registration Relevance respiratory Result safety profile secondary seriousness setting severity significant differences significantly Standard statistically survival survival time symptomatic took place treat Treatment treatment with colchicine Trial registration troponin was performed with COVID-19
[DOI] 10.1001/jamanetworkopen.2020.13136 PMC 바로가기 [Article Type] Research